Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.44 |
| ▸ | CNR2 | P34972 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 9/20 | 0.40 |
| ▸ | GAA | P10253 | 3/20 | 0.38 |
| ▸ | GLA | P06280 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | CASP1 | P29466 | 2/20 | 0.38 |
| ▸ | CASP7 | P55210 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.36 |
| ▸ | TDP2 | O95551 | 1/20 | 0.36 |
| ▸ | NSD2 | O96028 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23175233 | 0.78 | KDM4E (0.44) | KDM4EALDH1A1MAPTGAAHSD17B10 | |
| SCHEMBL1694060 | 0.76 | RAD52 (0.40) | CNR1CNR2KMT2A | |
| SCHEMBL1694063 | 0.76 | RAD52 (0.40) | CNR1CNR2KMT2A | |
| SCHEMBL12695177 | 0.76 | CNR1 (0.47) | CNR1CNR2KDM4EALDH1A1GAA | |
| SCHEMBL24388774 | 0.75 | CHRNB2 (0.48) | KDM4EALDH1A1MAPTGAAMEN1 | |
| SCHEMBL21276122 | 0.75 | CNR1 (0.51) | CNR1KDM4EALDH1A1GAAGLA | |
| SCHEMBL29865179 | 0.75 | MAP4K1 (0.38) | GAATDP2NSD2ABL1PLCG1 | |
| SCHEMBL19289585 | 0.74 | HDAC3 (0.40) | CNR1CNR2KDM4E | |
| SCHEMBL12686365 | 0.73 | CYP2C19 (0.53) | CNR1CNR2KDM4EALDH1A1MAPT | |
| SCHEMBL7299024 | 0.73 | ALDH1A1 (0.43) | KDM4EALDH1A1MAPTMAOBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2582703-A1 | HETEROARYL IMIDAZOLONE DERIVATIVES AS JAK INHIBITORS | Almirall S.A. (ES) | 2013-04-24 | — | — | EP | disclosed |
| US-20130089512-A1 | HETEROARYL IMIDAZOLONE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-04-11 | — | — | US | disclosed |
| US-20130089512-A1 | HETEROARYL IMIDAZOLONE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-04-11 | — | — | US | disclosed |
| US-20130089512-A1 | HETEROARYL IMIDAZOLONE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-04-11 | — | — | US | disclosed |
| WO-2012110860-A1 | TRICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-08-23 | — | — | WO | disclosed |
| WO-2011157397-A1 | HETEROARYL IMIDAZOLONE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2011-12-22 | — | — | WO | disclosed |
| WO-2011157397-A1 | HETEROARYL IMIDAZOLONE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2011-12-22 | — | — | WO | disclosed |
| EP-2397482-A1 | Heteroaryl imidazolone derivatives as jak inhibitors | Almirall, S.A. (ES) | 2011-12-21 | — | — | EP | disclosed |
| EP-2397482-A1 | Heteroaryl imidazolone derivatives as jak inhibitors | Almirall, S.A. (ES) | 2011-12-21 | — | — | EP | disclosed |
| EP-0308792-B1 | AZACHROMANE DERIVATIVES | MERCK PATENT GmbH (DE) | 1993-07-28 | — | — | EP | disclosed |
| US-4931454-A | Azachroman derivatives with effects on the cardiovascular system | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1990-06-05 | — | — | US | disclosed |
| EP-0308792-A2 | Azachromane derivatives | MERCK PATENT GmbH (DE) | 1989-03-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130089512-A1 | HETEROARYL IMIDAZOLONE DERIVATIVES AS JAK INHIBITORS | JAK2, JAK1, JAK3 | CNR1 3410/4885CNR2 3082/4885KDM4E 1319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.